President Joe Biden discussed several healthcare concerns during his State of the Union address, including reproductive rights, prescription drug costs, the Affordable Care Act and women's health research.
Bill Fera — a principal and head of AI at Deloitte — said that the generative AI frenzy holds incredibly promising opportunities for health systems. He noted that in order for hospitals to succeed in the era of generative AI, they need to establish the right metrics for their pilots early on so they can quickly nix or scale them.
Regardless of the path to market they ultimately take, DTx companies must be poised to harness and deploy data and information that can prove their products' economic value. Without it, the innovative treatments that they produce will continue to struggle to find success.
Amylyx Pharmaceuticals co-CEO Justin Klee previously said the company would withdraw ALS drug Relyvrio from the market if it failed its Phase 3 clinical trial. The biotech has set an eight-week timeline to evaluate its next steps.
Episode 2 of our Debunked show is now available. Editor-in-Chief Arundhati Parmar and co-host Samir Batra discuss unfair hospital pricing and what CA is trying to do starting April 1 to prevent too many large healthcare transactions involving CA healthcare entities that they could deem anticompetitive in nature.
No comments